Platelet Rich Plasma Market: Asia Pacific to Show Robust Growth between 2014 and 2020 In a recent report published by Transparency Market Research (TMR), a competitive study analyzing the global platelet rich plasma market is offered along with a market study irreplaceable for market players, stakeholders, and consultants of this industry. According to the study, the global platelet rich plasma market stood at US$0.16 billion in 2013. The market is estimated to expand at a CAGR of 11.9% during the period of 2014-2020 to reach US$0.35 billion by the end of the forecast period. The research report titled “Platelet Rich Plasma Market - Global Industry Analysis, Size, Share, Growth, Trends & Forecast 2014 - 2020� states that the rising awareness pertaining to platelet rich plasma (PRP) products and devices in developing economies is fueling the growth of the global platelets rich plasma market.
Platelet rich plasma (PRP) is a blood plasma derived product, which typically contains an elevated level of platelets and growth factors (at least four to eight times) than normal blood concentration. Increasing number of orthopedic surgeries and sports injuries, rising number of cosmetic surgeries, approval of new devices and discovery of new application areas and growing awareness amongst the global population are the prime factors driving the growth of global PRP market. According to the statistics provided by the International Society of Plastic and Aesthetic Surgeons (ISAPS), 11 million non-invasive cosmetic procedures were performed worldwide in 2013, including approximately 3.0 million dermal filler procedures. This extensive number of cosmetic surgeries performed is considered as one of the most prominent factor propelling the growth of the global PRP market during the forecast period from 2014 to 2020. Furthermore, increasing application areas such as erectile dysfunction and vampire facelift also support the market growth in the near future. However, high cost of the devices and therapy and threat of therapy failure are some of the factors restricting the market growth to some extent. P-PRP (Pure-PRP) segment was identified as the largest type of PRP in 2013. Extensive use of PPRP for orthopedic diseases and rich content of platelets and growth factors are expected to support the leadership position of the market segment. On the other hand, higher number of growth factors that promote rapid healing of injuries is likely to accelerate the L-PRF segment in the near future. In addition, cost effective platelet derivative, rich content of stem cells and leukocytes and high efficiency to treat diseases such as tendons and ligament injuries and neurological diseases are the other key factors that support the growth of L-PRF segment.